[18F]FPyQCP PET Imaging for Colorectal Cancer

This trial aims to test a new imaging drug, [18F]FPyQCP, to determine if it safely and effectively aids in detecting various cancers, including colorectal, gastric, pancreatic, lobular breast, and ovarian cancers. Participants will receive the drug, followed by a PET/CT scan to capture images of the cancer. As a Phase 1/2 study, it focuses on safety and the drug's potential effectiveness. Individuals with a confirmed diagnosis of one of these cancers, whether newly diagnosed, with suspected recurrence, or scheduled for a biopsy or surgery, might be suitable candidates. This trial seeks to understand how the drug works in people and measure its effectiveness in a smaller group, offering participants the chance to contribute to advancements in early-stage cancer detection.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have taken any radioisotopes or investigational drugs recently, and you should avoid certain contrast agents close to the trial dates.

Research shows that [18F]FPyQCP, the substance used in this trial, has been studied for safety and tolerability. In earlier studies, most participants tolerated [18F]FPyQCP well, with no serious side effects reported. This suggests that significant negative reactions were uncommon during the trials.

The studies conducted so far are in the early stages, focusing on safety. These initial studies indicate that [18F]FPyQCP has a good safety record, although more information is still being collected. Participants have not reported any major negative effects related to the treatment, which is promising for safety. However, ongoing research will provide more data to confirm these findings.

[18F]FPyQCP is unique because it uses a new imaging agent specifically designed for PET/CT scans to detect colorectal cancer. Current treatments often focus on surgical, chemotherapeutic, or traditional imaging approaches. Unlike these standard options, [18F]FPyQCP offers a potentially more precise method to visualize cancer, which could lead to better diagnosis and treatment planning. Researchers are excited because this imaging agent might provide clearer images, helping doctors identify tumors more accurately and earlier in the disease progression. This could ultimately improve patient outcomes by tailoring treatments more effectively to individual cases.

Studies have shown that PET/CT scans using the tracer [18F]FPyQCP might help detect certain cancers, including colorectal cancer (CRC). Although specific human data for [18F]FPyQCP remains limited, similar methods like [18F]FDG PET/CT have demonstrated high accuracy in detecting CRC. For instance, one study found that [18F]FDG PET/CT correctly identified CRC 100% of the time and correctly ruled it out 97% of the time. These findings suggest that PET scans with tracers like [18F]FPyQCP, which participants in this trial will receive, could be promising for early cancer detection, potentially aiding in early diagnosis and treatment planning.¹⁴⁶⁷⁸